Impact of the choice of an antiplatelet therapy for peripheral arterial disease: cost-effectiveness ratio and health economics assessment;Impact du choix d'un antiagrégant plaquettaire dans l'artériopathie oblitérante des membres inférieurs sur les pertes de chances et sur les coûts médicaux

Journal des Maladies Vasculaires

Volumn 32, Issue 1, 2007, Pages 8-14

  Priollet, P ^a   de Pouvourville, G ^b  

^a SAINT JOSEPH HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Aspirin; Clopidogrel; Cost effectiveness ratio; Health economics analyses; Losses of chances; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

ARTERY DISEASE; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM HEMORRHAGE; EUROPE; FRANCE; HEALTH ECONOMICS; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MORTALITY; COST BENEFIT ANALYSIS; ECONOMICS; PERIPHERAL VASCULAR DISEASE;

ASPIRIN; COST-BENEFIT ANALYSIS; HUMANS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 34247232554     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmv.2006.12.002     Document Type: Article

References (22)

1. Newman A.B. Peripheral arterial disease: Insights from population studies of older adults. J. Am. Geriatr. Soc. 48 (2000) 1157-1162
2. Weitz J.L., Byrne J., Clagett G.P., et al. Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review. Circulation 94 (1996) 3026-3049
3. Belch J.J., Topol E.J., Agnelli G., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch. Intern. Med. 163 (2003) 884-892
4. Boccalon H., Lehert P., and Mosnier M. Appréciation de la prévalence de l'artériopathie oblitérante des membres inférieurs en France à l'aide de l'index systolique dans une population à risque cardiovasculaire. J. Mal. Vasc. 25 (2000) 38-46
5. Programme national de réduction des risques cardiovasculaires 2002-2005. Ministère de l'Emploi et de la Solidarité. Accessible sur le site : http://www.sante.gouv.fr.
6. Prise en charge de l'artériopathie chronique oblitérante athéroscléreuse des membres inférieurs (indications médicamenteuses, de revascularisation et de rééducation). Recommandations de pratique clinique de la Haute Autorité de santé. Avril 2006.
7. Lechat P., and Priollet P. Prévention des évènements ischémiques majeurs au cours de l'artériopathie oblitérante des membres inférieurs : l'aspirine a-t-elle un rôle ?. J. Mal. Vasc. 31 (2006) 129-134
8. Singer E., Imfeld S., Hoffmann U., et al. Aspirin in peripheral arterial disease: breakthrough or pitfall?. Vasa 35 (2006) 174-177
9. CAPRIE Steering Committe. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348 (1996) 1329-1339
10. CNAMTS. Direction du service médical ; octobre 2005. http://www.ameli.fr.
11. http://www.atih.sante.fr.
12. Recommandations méthodologiques 2003 pour l'évaluation économique des stratégies de santé du Collège des économistes de la santé (CES) http://www.ces-asso.org/.
13. http:/www.ined.fr.
14. Caro J., Ishak K.J., and Migliaccio-Walle K. Estimating survival for cost effectiveness analyses: a case study in atherothrombosis. Value Health 7 (2004) 627-635
15. Beinart S.C., Kolm P., Veledar E., et al. Long-term cost-effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J. Am. Coll. Cardiol. 46 (2005) 761-769
16. Lamy A., Jonsson B., Weintraub W.S., et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur. J. Cardiovasc. Prev. Rehabil. 11 (2004) 460-465
17. Mahoney E.M., Mehta S., Yuan Y., et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am. Heart J. 151 (2006) 219-227
18. Karnon J., Brennan A., Pandor A., et al. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr. Med. Res. Opin. 21 (2005) 101-112
19. Schleinitz M.D., Weiss J.P., and Owens D.K. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am. J. Med. 116 (2004) 797-806
20. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PI-CURE study. Lancet 358 (2001) 527-533
21. Jones L., Griffin S., Palmer S., Main C., Orton V., Sculpher M., et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol. Assess. 8 (2004) 1-196
22. Technical considerations for cost-effectiveness analysis. WHO: the World Health Report 2002: reducing risks, promoting healthy life. Chapter 5, p. 108.